0001437749-24-012331.txt : 20240417 0001437749-24-012331.hdr.sgml : 20240417 20240417162118 ACCESSION NUMBER: 0001437749-24-012331 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240417 FILED AS OF DATE: 20240417 DATE AS OF CHANGE: 20240417 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schoen Eric CENTRAL INDEX KEY: 0001532303 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41905 FILM NUMBER: 24851331 MAIL ADDRESS: STREET 1: 7801 N. CAPITAL OF TX HWY STREET 2: SUITE 260 CITY: AUSTIN STATE: TX ZIP: 78731 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CASSAVA SCIENCES INC CENTRAL INDEX KEY: 0001069530 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 911911336 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6801 N CAPITAL OF TEXAS HIGHWAY STREET 2: BUILDING 1; SUITE 300 CITY: AUSTIN STATE: TX ZIP: 78731 BUSINESS PHONE: 512-501-2444 MAIL ADDRESS: STREET 1: 6801 N CAPITAL OF TEXAS HIGHWAY STREET 2: BUILDING 1; SUITE 300 CITY: AUSTIN STATE: TX ZIP: 78731 FORMER COMPANY: FORMER CONFORMED NAME: PAIN THERAPEUTICS INC DATE OF NAME CHANGE: 20000309 4 1 rdgdoc.xml FORM 4 X0508 4 2024-04-17 0001069530 CASSAVA SCIENCES INC SAVA 0001532303 Schoen Eric 6801 N CAPITAL OF TEXAS HWY, BLDG 1 SUITE 300 AUSTIN TX 78731 1 Chief Financial Officer 0 Common Stock 2024-04-17 4 M 0 1500 22 A 21300 D Common Stock 2000 I By limited liability corporation Common Stock Warrant 33 2024-01-03 4 A 0 7920 0 A 2024-01-03 2024-05-07 Common Stock 11880 7920 D Common Stock Warrant 33 2024-01-03 4 A 0 800 0 A 2024-01-03 2024-05-07 Common Stock 1200 800 I By limited liability corporation Common Stock Warrant 33 2024-04-17 4 M 0 1000 0 D 2024-01-03 2024-05-07 Common Stock 1500 6920 D Form 4 represents exercise for cash of common stock warrants received on January 3, 2024. Holder received one and one-half shares of common stock for each common stock warrant exercised. Represents warrants that were originally issued on January 3, 2024 as a pro-rata distribution to all holders of common shares. Each warrant entitles the holder to purchase one and one-half common shares at an exercise price of $33.00 per warrant. This distribution was exempt from immediate reporting under Section 16. /s/ Eric J. Schoen 2024-04-17